239 related articles for article (PubMed ID: 28939565)
21. Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study.
Donadini MP; Dentali F; Pegoraro S; Pomero F; Brignone C; Guasti L; Steidl L; Ageno W
Vasc Med; 2017 Dec; 22(6):518-524. PubMed ID: 28732457
[TBL] [Abstract][Full Text] [Related]
22. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA;
Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis.
Donadini MP; Ageno W; Antonucci E; Cosmi B; Kovacs MJ; Le Gal G; Ockelford P; Poli D; Prandoni P; Rodger M; Saccullo G; Siragusa S; Young L; Bonzini M; Caprioli M; Dentali F; Iorio A; Douketis JD
Thromb Haemost; 2014 Jan; 111(1):172-9. PubMed ID: 24154729
[TBL] [Abstract][Full Text] [Related]
24. Risk of venous thromboembolism in patients undergoing gastric cancer surgery: protocol for a systematic review and meta-analysis.
Wang D; Yu Y; Tao P; Wang D; Chen Y; Chen H
BMJ Open; 2020 Jan; 10(1):e033267. PubMed ID: 31919125
[TBL] [Abstract][Full Text] [Related]
25. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
27. Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol.
Yan AR; Samarawickrema I; Naunton M; Peterson GM; Yip D; Mortazavi R
BMJ Open; 2021 Dec; 11(12):e055322. PubMed ID: 34853112
[TBL] [Abstract][Full Text] [Related]
28. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE.
Ensor J; Riley RD; Moore D; Snell KI; Bayliss S; Fitzmaurice D
BMJ Open; 2016 May; 6(5):e011190. PubMed ID: 27154483
[TBL] [Abstract][Full Text] [Related]
29. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).
Tullett J; Murray E; Nichols L; Holder R; Lester W; Rose P; Hobbs FD; Fitzmaurice D
BMC Cardiovasc Disord; 2013 Mar; 13():16. PubMed ID: 23497371
[TBL] [Abstract][Full Text] [Related]
30. Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated.
Kearon C
J Thromb Thrombolysis; 2011 Apr; 31(3):295-300. PubMed ID: 21331558
[TBL] [Abstract][Full Text] [Related]
31. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.
Kearon C; Akl EA
Blood; 2014 Mar; 123(12):1794-801. PubMed ID: 24497538
[TBL] [Abstract][Full Text] [Related]
32. The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism - still a challenging issue.
Elmi G; Di Pasquale G; Pesavento R
Vasa; 2017 Mar; 46(2):87-95. PubMed ID: 28102773
[TBL] [Abstract][Full Text] [Related]
33. [Optimal duration of anticoagulation of venous thromboembolism].
Savina EN; Couturaud F
J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
[TBL] [Abstract][Full Text] [Related]
34. Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis.
Abdulrehman J; Elbaz C; Aziz D; Parpia S; Fazelzad R; Eischer L; Rodger MA; Cannegieter SC; Ten Cate-Hoek A; Nagler M; Schulman S; Rezende SM; Olié V; Palareti G; Marcucci M; Douketis J; Poli D; Zabczyk M; de Sousa DA; Miranda B; Cushman M; Tosetto A; Le Gal G; Kearon C; Skeith L
Br J Haematol; 2022 Oct; 199(1):130-142. PubMed ID: 35877546
[TBL] [Abstract][Full Text] [Related]
35. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
36. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.
Carrier M; Le Gal G; Wells PS; Rodger MA
Ann Intern Med; 2010 May; 152(9):578-89. PubMed ID: 20439576
[TBL] [Abstract][Full Text] [Related]
37. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Imberti D; Pomero F; Mastroiacovo D
Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579
[TBL] [Abstract][Full Text] [Related]
38. Risk stratification for recurrent venous thromboembolism in unprovoked venous thromboembolism patients.
Betancourt MT; Rodger MA
Acta Chir Belg; 2007; 107(6):636-40. PubMed ID: 18274176
[TBL] [Abstract][Full Text] [Related]
39. [Long-term treatment of venous thromboembolism].
Meyer G; Couturaud F
Rev Prat; 2015 Feb; 65(2):208-13. PubMed ID: 25939225
[TBL] [Abstract][Full Text] [Related]
40. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
Wang W; Su Y; Wu C; Sun Y; Dai N; Chen W; Zhang J; Xu Y; Brindis RG; Xu D; Li J
BMC Cardiovasc Disord; 2020 Feb; 20(1):53. PubMed ID: 32013892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
